SCHEMBL7120734

SCHEMBL7120734

CC(=O)Nc1ccc(Sc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)s1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.35
PKM P14618 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CHRNA7 P36544 1/20 0.34
SLC6A4 P31645 3/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A3 Q01959 2/20 0.33
EZH2 Q15910 1/20 0.33
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
PANK3 Q9H999 1/20 0.32
HTR3E A5X5Y0 1/20 0.30
HTR3B O95264 1/20 0.30
HTR3A P46098 1/20 0.30
HTR3D Q70Z44 1/20 0.30
HTR3C Q8WXA8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7121696 0.86 CHRNA7 (0.35) CHRNA7SLC6A4SLC6A2SLC6A3EZH2
SCHEMBL7124223 0.86 CHRNA7 (0.36) CHRNA7SLC6A4SLC6A2SLC6A3EZH2
SCHEMBL7120666 0.85 ITK (0.42)
SCHEMBL7114408 0.84 HDAC6 (0.37) CHRNA7SLC6A4SLC6A2SLC6A3EZH2
SCHEMBL7126699 0.84 CHRNA7 (0.36) CHRNA7SLC6A4SLC6A2SLC6A3
SCHEMBL7122463 0.83 CHRNA7 (0.36) HSD17B10CHRNA7SLC6A4SLC6A2SLC6A3
SCHEMBL7117116 0.83 CHRNA7 (0.42) HSD17B10CHRNA7SLC6A4SLC6A2SLC6A3
SCHEMBL7120663 0.83 SLC6A2 (0.38) CHRNA7SLC6A4SLC6A2SLC6A3EZH2
SCHEMBL7126926 0.83 KMT2A (0.39) GAAALDH1A1LMNA
SCHEMBL7226922 0.82 CHRNA7 (0.36) GAAHSD17B10CHRNA7SLC6A4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 GAA 1117/4885PKM 4801/4885ALOX15 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.